PATENT CLAIM ANALYSIS

Application Number: 16175206
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-05
Patent Classification: ["514", "384000"]

Abstract:
The invention provides novel compounds having the general formula I: wherein R 1 , R B1 , R B2 , n, p, q, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.

Claim (Index 18):
A method for the treatment of a disease or disorder in a human, the method comprising administration to the human of an effective treatment amount of a compound of  claim 1 , wherein the disease or disorder is selected from the group consisting of Parkinson's Disease, Lewy body dementia, multiple system atrophy, Parkinson-plus syndromes, tauopathies, Alzheimer's Disease, frontotemporal dementia, amyotrophic lateral sclerosis, spinal muscular atrophy, primary lateral sclerosis, Huntington's disease, ischemia, stroke, intracranial hemorrhage, cerebral hemorrhage, muscular dystrophy, progressive muscular atrophy, pseudobulbar palsy, progressive bulbar palsy, spinal muscular atrophy, inherited muscular atrophy, peripheral neuropathies, progressive supranuclear palsy, corticobasal degeneration, and demyelinating diseases.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 97.0
- Lexical Diversity: 1.48571
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12845045', '13002487', '11060463', '13725407', '14533358']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.756192889112611
- 35 USC 102 Novelty (BERT): 0.5366786295954835
- Combined Prediction Score: 0.7342414631608982
- Mean Citation Score: 326.0833320000001
- Max Citation Score: 345.5191
- Similarity Product: 185.6389242489696

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test